Skip to main content
Clinical Trials/CTRI/2017/11/010529
CTRI/2017/11/010529
Completed
Phase 4

Comparative Evaluation of Safety and Efficacy of Drotaverine Versus Mebeverine in Irritable Bowel Syndrome â?? A Randomized Double Blind Controlled Study. - Drotin DS/07/15

Walter Bushnell Pvt Ltd0 sites200 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Walter Bushnell Pvt Ltd
Enrollment
200
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
November 30, 2018
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Walter Bushnell Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • Patients between 18 to 80 years of either gender
  • Fulfillment of IBS Rome III criteria
  • Written informed consent

Exclusion Criteria

  • Failure to meet all inclusion criteria
  • Pregnant females
  • Patients with comorbid diseases, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF)
  • Patients taking drugs which modify or aggravate symptoms (antidepressants, calcium channel blockers etc)
  • Patients having hypothyroidism \& gluten hypersensitivity
  • Any history of fever, passage of blood in stool, loss of weight, any organic disease of GI tract in the recent past
  • Patients on any other concomitant medication for abdominal pain, bowel disturbance or altering gastrointestinal motility
  • Malignancy of any other organ

Outcomes

Primary Outcomes

Not specified

Similar Trials